3rd Annual Ligase Targeting Drug Development Summit
Evvnt Promotion / evvnt
Archiv

11.04.2023 - 13.04.2023 Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
Time: 9:00 am to 5:00 pm
Kongressthemen
From discovery to clinical development, the field of protein degradation is booming with excitement, with a whole host of investments and new companies joining the effort to successfully degrade unwanted or undrugged targets with key roles in a broad range of diseases from oncology to CNS, through to autoimmune.
Despite this, key challenges remain to rapidly and successfully discover novel and underexploited Ubiquitin E3 ligases.
From discovery to clinical development, the field of protein degradation is booming with excitement, with a whole host of investments and new companies joining the effort to successfully degrade unwanted or undrugged targets with key roles in a broad range of diseases from oncology to CNS, through to autoimmune.
Despite this, key challenges remain to rapidly and successfully discover novel and underexploited Ubiquitin E3 ligases.
Wissenschaftliche Fach-Gesellschaft
Hanson Wade
Hanson Wade
Anmerkungen
Speakers: Kirby Swatek, Principal Investigator, University of Dundee, Ian Churcher, Chief Scientific Officer, Amphista Therapeutics, David Duda, Senior Scientist, Johnson and Johnson and more.
Speakers: Kirby Swatek, Principal Investigator, University of Dundee, Ian Churcher, Chief Scientific Officer, Amphista Therapeutics, David Duda, Senior Scientist, Johnson and Johnson and more.
Anfragen und Anmeldung:
https://go.evvnt.com/1450513-2?pid=4832
Herr Alex Domingo
Gesundheitsversorgung, Public Health
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."